* 香港恒生创新药指数.HSIDI周三一度大涨5.9%，中国创新药资产的口头报告在美国一国际大会上数量创新高，券商称中国创新药产业及创新药投资有望持续迎来高景气。
* 石药集团1093.HK、中国生物制药1177.HK、再鼎医药9688.HK和信达生物1801.HK涨幅介于5.7-16.6%。
* 海通国际研报称，2025年美国临床肿瘤学会（ASCO）年会当地时间5/30-6/3在美国芝加哥举行。本次ASCO中国创新药资产的口头报告（oral+rapid oral+LBA）数量达73项，创历史新高。
研报指出，经过十余年来的发展，中国创新药已走到国际舞台中央，一个又一个交易额突破新高的海外BD反映了MNC对中国创新药资产的需求已远大于对地缘风险的担忧。随着头部创新药企已经开始批量进入扭亏为盈的新发展阶段，中生代Biotech旗下优质资产迎来BD浪潮开始密集出海，传统药企走出集采阴影、创新药业务进入兑现期迎来估值重估，中国创新药产业及创新药投资有望持续迎来高景气。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 宿泱韫; 审校 屈桂娟)
((jenny.su@thomsonreuters.com; 86-10-56692102;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.